Tech Company Financing Transactions
EG 427 Funding Round
EG 427 secured a $5.6 million Series A funding round on 7/13/2023. Backers included private investors.
Transaction Overview
Company Name
Announced On
7/13/2023
Transaction Type
Venture Equity
Amount
$5,620,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to finance clinical development of EG110A and advance other pipeline products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
29 rue du Faubourg Saint-Jacques
Paris, 75014
FR
Paris, 75014
FR
Phone
Undisclosed
Website
Email Address
Overview
EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. Our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our research capability is focussed on ensuring our powerful platform approach has wide applicability, with potential for many products across several therapeutic areas with severe unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philippe Chambon
Chief Marketing Officer
Cornelia Molkenteller
Chief Operating Officer
Samuel Salot
Chief Scientific Officer
Alberto Epstein
Co-Founder
François Giuliano
Browse more venture capital transactions:
Prev: 7/13/2023: Zluri venture capital transaction
Next: 7/13/2023: Mattilda venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs